225 results on '"Álvarez‐Román, María Teresa"'
Search Results
2. Switching and increasing prophylaxis regimen with a genetically recombinant fusion of coagulation factor IX and albumin in haemophilia B: a case report
3. No changes in hemostasis after COVID-19–heterologous vaccination schedule: A subanalysis of the phase 2 CombiVacS study
4. Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A
5. Hemostatic cover in orthopedic surgery
6. Moving towards Normalization of haemostasis and health equity: Evolving treatment goals for haemophilia A.
7. Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage
8. Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency
9. Management of acquired hemophilia A: results from the Spanish registry
10. Humanistic burden of haemophilia A without inhibitors: A cross‐sectional analysis of the HemoLIFE study.
11. Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management
12. Knee replacement surgery in a patient with acquired von Willebrand disease: a case study with recommendations for patient management
13. Simoctocog alfa (Nuwiq®) in children: early steps in life’s journey for people with severe hemophilia A
14. Haemophilia: Reasons for visits to the paediatric emergency department
15. Hemofilia: naturaleza de las visitas a urgencias pediátricas
16. Long-term clinical outcomes of prophylaxis with an rFVIIIFc or rFIXFc in adults aged ≥50 years with hemophilia A or B
17. A post hoc comparative real‐world analysis of HEAD‐US score for joint health assessment of patients with severe haemophilia A and B in Spain.
18. Suitability and readiness assessment of organizational resources for the implementation of gene therapy in hemophilia in Spain and Portugal: A survey-based study
19. Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A
20. Study of platelet kinetics in immune thrombocytopenia to predict splenectomy response
21. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)
22. Comparative analysis of Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) scores in persons with nonsevere hemophilia A and B reveals a high degree of joint damage in both disease types
23. Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A.
24. Study of platelet kinetics in immune thrombocytopenia to predict splenectomy response.
25. Hematological Concepts and Hematological Perioperative Treatment
26. Fitusiran prophylaxis in severe haemophilia without inhibitors
27. The 2021 guidelines on the diagnosis of von Willebrand disease: A comparison with current clinical practice in Spanish centers
28. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)
29. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial
30. No changes in haemostasis after COVID-19-heterologous vaccination schedule: a sub analysis of the phase 2 CombiVacS study
31. The Limitations and Unmet Needs of the Five Cornerstones to Guarantee Lifelong Optimization of Prophylaxis in Hemophilia Patients
32. Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study
33. Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
34. Predictive Value of Platelet Sequestration Studies in Splenectomy Response
35. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia
36. Acquired Haemophilia A: A 15-Year Single-Centre Experience of Demography, Clinical Features and Outcome
37. Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors
38. The factor VIII treatment history of non‐severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEAD‐US system
39. Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A
40. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
41. Hematological Concepts and Hematological Perioperative Treatment
42. Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa
43. Impact of Age on Hemostasis of Patients with Immune Thrombocytopenia
44. Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children
45. Coagulation in Patients with Immune Thrombocytopenia and Other Associated Autoimmune Disorders
46. Avatrombopag in Immune Thrombocytopenia (ITP). Real-Life Experience of Its Use in Hospitals within the Community of Madrid, Spain (AVAMAD STUDY)
47. The Importance of Platelet Glycoside Residues in the Haemostasis of Patients with Immune Thrombocytopaenia
48. Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD‐US system
49. COVID‐19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery
50. Insights into the Procoagulant Profile of Patients with Systemic Lupus Erythematosus without Antiphospholipid Antibodies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.